Compare Kohl's Corporation (KSS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Medpace Holdings Inc — how do they compare? Kohl's Corporation trades at $20.36 (market cap $2.28B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 7.4× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.49% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Medpace Holdings Inc for 14 Days on average.
| KSS | MEDP | |
|---|---|---|
Market Cap | $2.28B | $16.82B |
Volume | 4,960,280 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $630.19 |
52-Week Low | $11.72 | $393.42 |
Typical Hold Time | 48 Days | 14 Days |
Enterprise Value | $7.88B | $16.44B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $20.35, up 1.14% with a bullish technical outlook despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, though revenue has declined from $19.4B in 2022 to $16.2B in 2025. Recent Q2 2026 earnings beat expectations with $1.28 EPS versus $0.58 expected, and the company raised full-year guidance amid merchandising improvements.
KSS presents a value opportunity with strong fundamentals but faces headwinds from 18 consecutive quarters of declining sales. Analyst consensus is mixed with 30% buy ratings and a $15.50 price target below current levels. The turnaround story depends on holiday execution and sales stabilization to sustain recent gains beyond tariff-related benefits.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
